ProCE Banner Activity

Mutations After Mutations: Prevention With COVID-19 Vaccines and Monoclonal Antibodies 

Clinical Thought

In this expert commentary, I review key studies from IDWeek 2024 regarding the prevention of COVID-19, its vaccines, and the use of monoclonal antibodies for immunocompromised patients. 

Released: November 20, 2024

Expiration: November 19, 2025

Share

Faculty

Marcus Pereira

Marcus Pereira, MD, MPH, FAST

Associate Professor of Medicine at CUIMC
Director of Clinical Services
Division of Infectious Diseases
Medical Director
Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with ProCE, LLC

ProCE Banner

Supporters

This program is supported by an educational grant from AstraZeneca

AstraZeneca

Partners

ProCE

ProCE Banner

Disclosure

Primary Author

Marcus Pereira, MD, MPH, FAST

Associate Professor of Medicine at CUIMC
Director of Clinical Services
Division of Infectious Diseases
Medical Director
Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York

Marcus Pereira, MD, MPH, FAST: consultant/advisor/speaker: Merck, Synklino, Takeda.